Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

Emily Coleman; Gauri Panse; Jason Haldas; Scott N Gettinger; Jonathan S Leventhal

doi:10.1016/j.jdcr.2018.06.022

Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

JAAD Case Rep. 2018 Aug 9;4(7):669-671. doi: 10.1016/j.jdcr.2018.06.022. eCollection 2018 Aug.

Authors

Emily Coleman¹, Gauri Panse^{1

2}, Jason Haldas³, Scott N Gettinger³, Jonathan S Leventhal¹

Affiliations

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
² Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
³ Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.

No abstract available

Keywords: IL, interleukin; PD-1, programmed death 1; PRP, pityriasis rubra pilaris; Th, helper T cell; acitretin; immune-related adverse event; irAE, immune-related adverse event; pembrolizumab; pityriasis rubra pilaris.

Publication types

Case Reports